Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.
Phase of Trial: Phase IV
Latest Information Update: 12 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PROPHESYS-2
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 04 Apr 2016 Time frame for Virological Response changed from weeks 4 and 12, and 12 and 24 weeks after end of treatment to 24 weeks after end of treatment.
- 15 Feb 2012 Actual patient number changed from 2271 to 2272 as reported by ClinicalTrials.gov.